EMA: Deworming Med Linked to Brain Side Effects
- A widely used anthelmintic drug, levamisole, is under scrutiny by the European Medicines Agency (EMA) due to emerging links wiht a rare but debilitating neurological condition called leukoencephalopathy.
- Leukoencephalopathy is a term encompassing a group of rare disorders that affect the white matter of the brain.
- the severity of leukoencephalopathy varies significantly depending on the specific type and extent of brain damage.
Levamisole and Leukoencephalopathy: EMA Review of Anthelmintic Drug
Table of Contents
A widely used anthelmintic drug, levamisole, is under scrutiny by the European Medicines Agency (EMA) due to emerging links wiht a rare but debilitating neurological condition called leukoencephalopathy. This review, initiated in early 2024, raises concerns for both human and veterinary medicine, as levamisole is used to treat parasitic worm infections in both populations.
Understanding Leukoencephalopathy
Leukoencephalopathy is a term encompassing a group of rare disorders that affect the white matter of the brain. This damage disrupts normal brain function, leading to a range of neurological symptoms. These can include:
- Cognitive impairment (memory loss, difficulty thinking)
- Motor problems (weakness, difficulty walking, tremors)
- Behavioral changes
- Seizures
the severity of leukoencephalopathy varies significantly depending on the specific type and extent of brain damage. Diagnosis often requires advanced imaging techniques like MRI.
Levamisole: Uses and Concerns
Levamisole is an anthelmintic medication, meaning it’s used to treat infections caused by parasitic worms. It’s commonly used in veterinary medicine to deworm livestock, particularly cattle and pigs. In human medicine, it has been used to treat worm infections, though its use is less widespread due to the availability of option treatments. Historically,it was also investigated for its potential immunomodulatory effects.
The concern arises from a growing number of reported cases of leukoencephalopathy in individuals with a history of levamisole exposure. While a direct causal link hasn’t been definitively established, the temporal association and the consistency of the neurological presentation have prompted the EMA to investigate.
The EMA Review Process
The EMA’s review is being conducted by the Pharmacovigilance Risk Assessment Committee (PRAC). The PRAC is responsible for assessing the risks associated with medicines and making recommendations on how to minimize those risks. The review process typically involves:
- Data Collection: gathering all available data on levamisole use and reported cases of leukoencephalopathy.
- Risk Assessment: Evaluating the strength of the evidence linking levamisole to the disease.
- Benefit-Risk Evaluation: Weighing the benefits of levamisole against the potential risks.
- Proposal: The PRAC will issue recommendations, which may include restricting the use of levamisole, adding warnings to the product label, or even withdrawing the drug from the market.
The EMA anticipates issuing its recommendations in late 2025.These recommendations will be binding on all EU member states.
Who is Affected?
The potential impact of this review extends to several groups:
- Patients: Individuals who have used levamisole,particularly those experiencing neurological symptoms,should consult their healthcare provider.
- Veterinarians: Veterinarians who use levamisole to treat livestock need to be aware of the potential risks and monitor their animals for any signs of neurological illness.
- Farmers: Farmers who raise livestock treated with levamisole should be aware of the potential for residues in meat and other animal products.
- Pharmaceutical Companies: Manufacturers of levamisole will need to comply with any restrictions or changes imposed by the EMA.